Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Triple-class relapsed/refractory multiple myeloma (RRMM) presents a significant clinical challenge with limited treatment options.
• Belantamab mafadotin, an antibody-drug conjugate targeting BCMA, offers a potential therapeutic avenue.

Purpose of the Study:

• To evaluate the clinical outcomes of Belantamab mafadotin in combination with dexamethasone (Bd) for patients with triple-class RRMM.
• To assess the efficacy and safety profile of the Bd regimen in this heavily pretreated patient population.

Main Methods:

• Retrospective analysis of 35 patients with triple-class RRMM treated with Bd at the University of Kansas.
• Data collection included patient demographics, prior therapies, disease characteristics, response rates, survival outcomes, and adverse events.

Main Results:

• The overall response rate (ORR) was 43%, with 23% achieving very good partial response or better.
• Median progression-free survival (PFS) was 4.9 months and median overall survival (OS) was 10.7 months.
• The most common adverse event was keratopathy (86%), leading to dose modifications in 69% of patients. Other toxicities included anemia (83%) and thrombocytopenia (80%).

Conclusions:

• Belantamab mafadotin plus dexamethasone demonstrates notable activity in triple-class RRMM.
• Keratopathy is a significant and challenging adverse event associated with Bd therapy, frequently necessitating dose reductions, delays, or treatment discontinuation.